Dynamic Gait Index As a Functional Gait Assessment Measure in Children with JIA
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Mar 5, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a tool called the Dynamic Gait Index (DGI) to see if it can help assess walking difficulties in children with Juvenile Idiopathic Arthritis (JIA). JIA is a condition that causes pain and swelling in the joints, which can make it hard for kids to walk properly and enjoy their daily activities. The DGI tests various walking skills, such as walking straight, changing speeds, and navigating around obstacles. Researchers want to find out if this tool is effective for children aged 8 to 16 who have JIA, as there aren’t many ways to measure walking difficulties in these kids right now.
To participate in this study, children must be diagnosed with JIA and have issues with one knee that affects their walking. They should be between 8 and 16 years old and able to follow simple instructions. There is also a control group made up of children without any health issues that might affect walking. Participants can expect to take part in walking tests using the DGI, which will help researchers understand if this tool can accurately assess walking in children with JIA, potentially leading to better care and support for these patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Study Group;
- • Having a JIA diagnosis according to ILAR criteria between the ages of 8-16,
- • Having unilateral knee joint involvement that will affect walking
- • Being compatible, volunteer and cooperative in the study Control Group;
- • 1. Not having any neurological or orthopedic diagnosis
- • 2. Being between the ages of 8-16
- • 3. Being at a mental level that can understand the commands of the person performing the evaluation
- Exclusion Criteria:
- • Study Group;
- • Having an additional neurological or orthopedic diagnosis accompanying JIA and affecting treatment results,
- • Having lower extremity asymmetry or active lower extremity involvement other than the knee joint that will affect walking.
- • Control Group;
- • -Having any health problem that may affect the study
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, Buyukcekmece, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported